Mammalian ribonucleotide reductase (mRR) is a chemotherapeutic target. The enzyme is composed of 2 subunits (mR1 and mR2) and is inhibited by Ac-FTLDADF (denoted P7), corresponding to the C-terminus of mR2, which competes with mR2 for binding to mR1. mRR has 2 physiologically important active forms,
Structure–activity relationships of benzohydroxamic acid inhibitors of ribonucleotide reductase
✍ Scribed by Bart Van't Riet; Lemont B. Kier; Howard L. Elford
- Publisher
- John Wiley and Sons
- Year
- 1980
- Tongue
- English
- Weight
- 243 KB
- Volume
- 69
- Category
- Article
- ISSN
- 0022-3549
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable v
## Abstract The principal component regression analysis is used when the predicting variables correlate significantly against the regressor variables and, when a collinearity and multicollinearity exist among regressor variables. The example adapted from enzymology shows that no loss of information
## Abstract Aiming at new drugs to efficiently treat diseases, in which either increased or decreased levels of active vitamin D are desirable, we have designed some 400 structurally different azole‐type inhibitors and examined their capacity to selectively block vitamin D metabolism by CYP24 or sy